RVVTF - Revive Therapeutics Ltd.

Other OTC - Other OTC Delayed Price. Currency in USD
0.12652
-0.00178 (-1.39%)
At close: 3:54PM EDT
Stock chart is not supported by your current browser
Previous Close0.12830
Open0.13770
Bid0.00000 x 0
Ask0.00000 x 0
Day's Range0.12652 - 0.13770
52 Week Range0.11200 - 0.39820
Volume12,566
Avg. Volume48,653
Market Cap7.525M
Beta (3Y Monthly)-0.56
PE Ratio (TTM)N/A
EPS (TTM)-0.02500
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • GlobeNewswirelast month

    Revive Therapeutics Introduces RELICANN™ a New Brand for Hemp-based CBD Wellness and Medical Cannabis Market

    Revive Therapeutics Ltd. (TSX VENTURE: RVV) (RVVTF) (31R.F) (“Revive” or the “Company”), a specialty cannabis company focused on the research, development and commercialization of novel cannabinoid-based products, today announced the introduction of RELICANN™, the Company’s hemp-based  and medical cannabis brand designed for the health and wellness and medical cannabis consumer.  The Company’s first product under the RELICANN™ brand is RELICANN™ hemp-based Cannabidiol (“CBD”) gum, which will be available in Canada in the fourth-quarter of 2018. RELICANN™ hemp-based CBD gum is a patented controlled-release cannabinoid chewing gum containing 50 mg of hemp oil and 10 mg of CBD.  Based on an oral mucosal delivery system a research study has shown the absorption rate of CBD to be at least 75% in just 30 minutes of chewing.  The RELICANN™ hemp-based CBD gum is a distinct and alternative option from traditional oral forms of hemp (i.e.

  • GlobeNewswire2 months ago

    Revive Therapeutics Provides Update on its Cannabis-based Pharmaceuticals Initiatives

    Revive Therapeutics Ltd. (TSX VENTURE: RVV) (RVVTF) (31R.F) ("Revive" or the “Company”), a specialty cannabis company focused on the research, development and commercialization of novel cannabis-based products, is pleased to provide an update on its cannabis-based pharmaceuticals initiatives in its objective in offering novel therapies for unmet medical needs and rare diseases.

  • GlobeNewswire2 months ago

    Revive Therapeutics Provides Corporate Update

    Revive Therapeutics Ltd. (TSX VENTURE: RVV) (RVVTF) (31R.F) (“Revive” or the “Company”), a specialty cannabis company focused on the research, development and commercialization of novel cannabinoid-based products, is pleased to provide a corporate update on its product strategy and business development activities in its objective in offering best-in-class products with first mover advantage in the multi-billion global cannabis market. About Revive Therapeutics Ltd.

  • GlobeNewswire2 months ago

    AXIM® Biotechnologies Enters Canadian Market Through New Exclusive Distribution and License Agreement With Revive Therapeutics

    NEW YORK, Aug. 27, 2018-- AXIM ® Biotechnologies, Inc., a world leader in cannabinoid research and development, today announced that it has signed an exclusive distribution and license agreement with Revive ...

  • GlobeNewswire2 months ago

    Revive Therapeutics Applies To FDA For Orphan Drug Designation of Cannabidiol For Treatment Of Liver Transplantation

    Revive Therapeutics Ltd. (TSX VENTURE:RVV) (RVVTF) (31R.F) (“Revive” or the “Company”), a specialty medical cannabis company, today announced that it has submitted an application to the U.S. Food and Drug Administration (“FDA”) seeking orphan drug designation of cannabidiol (“CBD”) for the treatment of hepatic ischemia and reperfusion injury (“IRI”) during liver transplantation. Liver ischemia-reperfusion injury is a major complication of liver transplantation and is one of the leading causes for post-surgery hepatic dysfunction leading to an increased risk of postoperative morbidity and mortality.  According to the United Network for Organ Sharing (“UNOS”) there have been 160,722 liver transplants performed between January 1, 1988 and July 30, 2018.  Currently there are 13,773 individuals on the waiting list for a liver transplant.  Quickly restoring blood supply of ischemic liver as soon as possible is crucial for avoiding or reducing injury from ischemia, whereas strategies used to attenuate the damage induced by reperfusion, including ischemic preconditioning, ischemic postconditioning, and machine perfusion.  These strategies are expensive, sometimes hard to perform in clinical surgeries, and difficult in maintaining liver functions in the case of acute injuries.  Revive believes that the immunosuppressant and anti-inflammatory protective effects of CBD  may provide a novel, more beneficial strategy to attenuate the damage induced by ischemia and reperfusion during liver transplantation.

  • Marketwired10 months ago

    Revive Therapeutics Announces Update on its Collaboration Agreement with Health Canada Licensed Dealer for Medical Cannabis...

    Revive Therapeutics Ltd. , a company focused on the research, development and commercialization of novel therapies and technologies for the medical cannabis and cannabinoid-based pharmaceutical markets, ...

  • Marketwired10 months ago

    Revive Therapeutics Enters into Collaboration Agreement with Health Canada Licensed Dealer for Medical Cannabis and US FDA Approved Laboratory

    Revive Therapeutics Ltd. , a company focused on the research, development and commercialization of novel therapies and technologies for the medical cannabis and pharmaceutical sectors, is pleased to announce ...

  • Marketwired11 months ago

    Revive Therapeutics Announces Update on Development of Datametrex Artificial Intelligence Component in Blockchain Enabled Patient-Focused Program for Medical Cannabis Sector

    Revive Therapeutics Ltd. , a company focused on the research, development and commercialization of novel therapies and technologies for the medical cannabis and pharmaceutical sectors, today announced ...

  • Marketwired11 months ago

    Revive Therapeutics Announces Results for the Three Months Ended September 30, 2017

    Revive Therapeutics Ltd. , a company focused on the research, development and commercialization of novel therapies and technologies for the medical cannabis and pharmaceutical sectors, today...

  • Marketwired11 months ago

    Revive Therapeutics Announces Results for the Three Months Ended September 30, 2017

    Revive Therapeutics Ltd. , a company focused on the research, development and commercialization of novel therapies and technologies for the medical cannabis and pharmaceutical sectors, today announced ...

  • Marketwired11 months ago

    Revive Therapeutics Announces Successful Final Results of Novel Cannabinoid Delivery Technology Unlocking Commercialization Opportunities in the Medical Cannabis and Pharmaceutical Sectors

    Revive Therapeutics Ltd. , a company focused on the research, development and commercialization of novel therapies and technologies for the medical cannabis and pharmaceutical sectors, today announced ...